LOXOF 250MG TABLET

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

The exact mechanism of action for Hemi is not explicitly detailed in the available resources, but compounds with similar structure may act by modulating neurotransmitter levels, inhibiting enzymes, or affecting cellular signaling pathways.

Pharmacodynamics

Hemi may exhibit pharmacodynamic properties that include modulation of neural activity or inhibition of specific biochemical pathways. Its effects could be dose-dependent and vary based on the therapeutic context.

Pharmacokinetics

The pharmacokinetic profile of Hemi, including absorption, distribution, metabolism, and excretion, is not well-documented in the provided resources. Generally, compounds in this class may undergo first-pass metabolism and have a variable half-life.

Dosage

Children: Refer to the specific formulation or active ingredient for dosing information.

Adults: Refer to the specific formulation or active ingredient for dosing information.

Mechanism of action

The mechanism of action of hemihydrate forms of drugs can vary widely depending on the specific compound. In many cases, the hemihydrate form enhances the solubility of the active ingredient, which facilitates its dissolution and absorption in the gastrointestinal tract.

Pharmacodynamics

Pharmacodynamics of hemihydrate compounds generally relates to the pharmacological effects that arise from the active drug once it is absorbed. The effects may vary based on the specific drug and its therapeutic target, but overall, the hemihydrate form aims to improve efficacy by ensuring adequate plasma concentrations are achieved more effectively than non-hydrated forms.

Pharmacokinetics

The pharmacokinetics of hemihydrate drugs typically demonstrate improved dissolution rates due to the presence of water, which can lead to increased absorption. This may result in quicker onset of action and modified half-lives. The specifics of absorption, distribution, metabolism, and excretion will depend on the active ingredient and its properties.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from moisture and heat. Keep container tightly closed.

Indications

• Community-acquired pneumonia
• Chronic bronchitis exacerbation
• Acute bacterial sinusitis
• Uncomplicated urinary tract infections
• Complicated urinary tract infections
• Skin and soft tissue infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing.

Adults: Refer to specific clinical guidelines or the BNF for appropriate dosing.

Mechanism of action

Levofloxacillin exerts its antibacterial effect by inhibiting the bacterial enzyme DNA gyrase and topoisomerase IV, which are essential for DNA replication, transcription, and repair. This inhibition disrupts the DNA supercoiling necessary for bacterial cell division and replication, ultimately leading to bacterial cell death.

Pharmacodynamics

Levofloxacillin demonstrates concentration-dependent bactericidal activity, meaning that higher concentrations result in greater bacterial killing. The drug has a prolonged post-antibiotic effect, allowing for less frequent dosing. The in vitro activity of levofloxacillin is characterized by a time-kill effect, where the rate of killing increases with increasing drug concentrations. It is effective against a wide range of bacteria, including Streptococcus pneumoniae, Escherichia coli, and Haemophilus influenzae.

Pharmacokinetics

Levofloxacillin is well-absorbed following oral administration, with a bioavailability of approximately 100%. It reaches peak plasma concentrations within 1 to 2 hours after dosing. The drug is widely distributed throughout body tissues and fluids, including the lungs and prostate. It has a half-life of about 6 to 8 hours, allowing for once-daily dosing in many cases. Levofloxacillin is primarily excreted unchanged in the urine, making renal function an important consideration in dosing adjustments for patients with impaired kidney function.

Contra-indications

• Hypersensitivity to levofloxacin or other fluoroquinolones
• History of tendon disorders related to fluoroquinolone use
• Concurrent use with tizanidine

Adverse effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Sleep disturbances
• Tendon rupture
• QT interval prolongation
• Photosensitivity reactions
• Clostridium difficile-associated diarrhea

Interactions

• Antacids containing magnesium or aluminum may reduce absorption
• Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of CNS stimulation
• Warfarin may have its effects altered
• Drugs that prolong the QT interval

Precautions

• Use with caution in patients with a history of seizures
• Patients with renal impairment may require dosage adjustments
• Monitor for signs of tendon damage, especially in older adults
• Caution in patients with myasthenia gravis as it may exacerbate muscle weakness

Pregnancy

Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended as safety in pregnant women has not been established.

Breast-feeding

Levofloxacin is excreted in breast milk. Caution should be exercised when administering to a nursing mother. Alternatives should be considered if the drug is essential.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Injection solution
• Oral solution